Barrington Research Equities Analysts Boost Earnings Estimates for DENTSPLY SIRONA Inc (XRAY)

DENTSPLY SIRONA Inc (NASDAQ:XRAY) – Equities research analysts at Barrington Research boosted their Q2 2019 earnings estimates for shares of DENTSPLY SIRONA in a research report issued on Monday, May 6th. Barrington Research analyst M. Petusky now anticipates that the medical instruments supplier will post earnings of $0.57 per share for the quarter, up from their previous forecast of $0.56. Barrington Research currently has a “Outperform” rating and a $63.00 target price on the stock. Barrington Research also issued estimates for DENTSPLY SIRONA’s FY2019 earnings at $2.32 EPS, Q1 2020 earnings at $0.56 EPS, Q2 2020 earnings at $0.63 EPS, Q3 2020 earnings at $0.63 EPS, Q4 2020 earnings at $0.77 EPS and FY2021 earnings at $2.90 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Friday, May 3rd. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.10. The company had revenue of $946.20 million during the quarter, compared to analysts’ expectations of $925.13 million. DENTSPLY SIRONA had a positive return on equity of 8.98% and a negative net margin of 26.48%. DENTSPLY SIRONA’s quarterly revenue was down 1.0% on a year-over-year basis. During the same period last year, the business earned $0.45 earnings per share.



Several other research analysts have also recently weighed in on the company. HC Wainwright set a $49.00 price target on DENTSPLY SIRONA and gave the company a “hold” rating in a research report on Friday, April 5th. William Blair upgraded DENTSPLY SIRONA from a “market perform” rating to an “outperform” rating and set a $56.71 price target for the company in a research report on Monday, March 18th. UBS Group initiated coverage on DENTSPLY SIRONA in a research report on Thursday, January 17th. They set a “neutral” rating and a $42.00 price target for the company. Robert W. Baird lifted their price target on DENTSPLY SIRONA from $42.00 to $50.00 and gave the company a “neutral” rating in a research report on Monday, March 4th. Finally, Bank of America initiated coverage on DENTSPLY SIRONA in a research report on Monday, March 18th. They set a “buy” rating and a $57.00 price target for the company. Nine investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. DENTSPLY SIRONA has an average rating of “Buy” and an average price target of $53.25.

Shares of XRAY stock opened at $54.99 on Thursday. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.86 and a quick ratio of 1.27. The company has a market cap of $12.19 billion, a P/E ratio of 27.36, a P/E/G ratio of 2.25 and a beta of 1.11. DENTSPLY SIRONA has a twelve month low of $33.93 and a twelve month high of $55.88.

A number of institutional investors and hedge funds have recently modified their holdings of XRAY. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of DENTSPLY SIRONA in the fourth quarter worth approximately $26,000. Private Capital Group LLC boosted its stake in shares of DENTSPLY SIRONA by 105.3% in the fourth quarter. Private Capital Group LLC now owns 700 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 359 shares during the last quarter. Pinnacle Bank acquired a new stake in shares of DENTSPLY SIRONA in the fourth quarter worth approximately $26,000. Truehand Inc acquired a new stake in shares of DENTSPLY SIRONA in the fourth quarter worth approximately $27,000. Finally, Enlightenment Research LLC acquired a new stake in shares of DENTSPLY SIRONA in the fourth quarter worth approximately $30,000. 99.78% of the stock is currently owned by institutional investors.

In other DENTSPLY SIRONA news, SVP Daniel P. Key acquired 3,697 shares of the company’s stock in a transaction on Tuesday, May 7th. The shares were bought at an average cost of $54.68 per share, with a total value of $202,151.96. Following the completion of the acquisition, the senior vice president now owns 9,024 shares in the company, valued at $493,432.32. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Eric Brandt sold 9,160 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $53.45, for a total value of $489,602.00. Following the completion of the sale, the director now directly owns 26,003 shares in the company, valued at $1,389,860.35. The disclosure for this sale can be found here. 0.62% of the stock is currently owned by company insiders.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 12th. Shareholders of record on Friday, March 29th were issued a $0.087 dividend. This represents a $0.35 annualized dividend and a yield of 0.63%. The ex-dividend date was Thursday, March 28th. DENTSPLY SIRONA’s payout ratio is currently 17.41%.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Further Reading: What is a stock split?

Earnings History and Estimates for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.